Programme
DÉFICIENCE INTELLECTUELLE D’ORIGINE GÉNÉTIQUE :
PROGRÈS VERS DES TRAITEMENTS CIBLÉS
THURSDAY MARCH 24
14:00: Welcome - Jean-Marie Le Mene
14:10: General Introduction - Randi Hagerman
The Genetic Level: Genomic Perturbations in Intellectual Disability Disorders
and Therapeutic Possibilities
14:40: The new angle in mental retardation: the Non-Coding Genome - Stylianos Antonarakis
15:10: In the search for mental retardation genes important for therapy
15:40: Coffee Break
Communications
16:10: Changes in genome structure in clinics of mental retardation
16:40: Modeling the genomic problem: the mouse genomic library - Yann Herault
17:10: Exome sequencing
17:40: MicroRNAs as a molecular basis for mental retardation
18:10: Going to therapy: ALD clinical trials with AAV
FRIDAY MARCH 25
The Cellular Level: Synaptic and Cerebral Plasticity and Pharmacological Intervention
09:00: Neurobiological Advances leading to treatment - William Mobley
9:30: Targeting the stuff memories are made of: Rho and others - Ger J.A. Ramakers
Communications
10:00: Molecular basis of pharmacological therapies for cognition - Katheleen Gardiner
10:30: Coffee Break
11:00: Dyrk1a inhibitors in mice and men
11:15: GABA inverse agonist for treating Down syndrome cognitive deficits - Marie-Claude Potier
11:30: New GABA molecules
11:50: Shh agonists for treating Down syndrome cognitive deficits
12:10: Down syndrome and Alzheimer disease targets - Gilbert Di Paolo
12:30: Lunch
The Cognitive Level, Phenotypic Assessment and Evaluation of Therapeutic Success
14:00: Quantitative measure of CNS dysfunction - Randi Hagerman
14:15: Neuropsychological evaluation tools for diagnosis and evaluation of treatment - Lynn Nadel
Communications
14:45: Neuroimaging and the cognitive phenotype: a critical review of new findings - Ira Lott
15:15: FMR1
15:30: Coffee Breack
Clinical Trails for Intellectual Disability Syndromes
16:00: Common targets in mental retardation - Mara Dierssen
Communications
16:30: FMR1 Molecular Advances: treatment Issues - Paul Hagerman
17:00: Xfra: clinical trials of targeted treatments - Sébastien Jacquemont
17:45: Xfra: clinical trials of targeted treatments
18:30: Posters session
SATURDAY MARCH 26
09:00: Folates and Down syndrome - Henri Blehaut
09:15: Folates and Rett syndrome
09:45: Rapamycin trials
10:15: New treatments for SMS
10:30: Coffee Break
11:00: Treatment of GAMT deficit
11:15: The transcriptome program to explore new therapeutic pathways
11:30: TBD
11:45: Jerome Lejeune Posters Awards - Randi Hagerman
12:00: Conclusion
Pour visualiser ces documents,
vous devez disposer d’Adobe Acrobat Reader.
English version